Drug intelligence / Profile preview

SUICIDE + immunogene therapy

Development stage
Preclinical
Modality
Vaccines & Immunotherapeutics, Gene Therapies
Administration
Intratumoral, Intravenous (depending On Delivery Method)
01

Overview

SUICIDE + immunogene therapy refers to a combination approach in cancer treatment that merges "suicide gene therapy" with "immunogene therapy." Suicide gene therapy involves introducing genes into tumor cells that encode enzymes capable of converting non-toxic prodrugs into toxic compounds, selectively killing the modified cancer cells. Immunogene therapy uses genetic modification to enhance the immune system's ability to recognize and attack tumor cells, often by increasing the expression of immune-stimulatory molecules or tumor antigens. The combined modality aims both to directly kill cancer cells (via suicide gene activation) and stimulate a robust anti-tumor immune response (via immunogenic cell death and/or enhanced antigen presentation). This strategy is experimental and primarily investigated in preclinical models or early-phase clinical trials for various cancers[6].

02

Targets

DNA polymerase familyCSF2R (Granulocyte-macrophage colony-stimulating factor receptor)HSV-TK (Herpes simplex virus type 1 thymidine kinase (HSV1-TK))GM-CSF (Granulocyte-macrophage colony-stimulating factor)

Beyond the preview

Go deeper on SUICIDE + immunogene therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUICIDE + immunogene therapy.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call